Guardant Complete leads the way in precision oncology testing.
Our proprietary, cutting-edge technology measures changes in circulating tumor DNA (ctDNA) to1:
+ Get a highly sensitive, minimally invasive
assessment of cancer11+ Detect spatial and temporal evolution of a tumor12
The Guardant Complete
portfolio is backed by data from:
>300,000 patients tested
>80 clinical outcomes
studies
>400 peer-reviewed
publications
A wide array of precision oncology assays and comprehensive support, all conveniently accessible in one, intuitive portal.
Partner with Guardant Health and experience seamless customer service, including:
-
+
One intuitive portal to conveniently order all tests
-
+
End-to-end billing assistance with Guardant Access
-
+
Mobile phlebotomy for convenient sample collection
-
+
On-demand support from Guardant Health Medical Affairs
Guardant Complete can transform how
you make critical treatment decisions
across the cancer continuum.3,9
SWIPE TO REVEAL FULL TABLE
References: 1. Guardant360® CDx Technical Information. Guardant Health, Inc. Redwood City, CA. July 2021. 2. Guardant360 TissueNext™ Assay Specifications. Guardant Health, Inc. Redwood City, CA. 3. Backgrounder: Guardant Reveal™ liquid biopsy test. Guardant Health, Inc. Redwood City, CA. 4. Parikh AR, Van Seventer EE, Siravegna G, et al. Minimal residual disease detection using a plasma-only circulating tumor DNA assay in patients with colorectal cancer. Clin Cancer Res. 2021;27(20):5586-5594. doi:10.1158/1078-0432.CCR-21-0410
5. FDA News Release. FDA approves first liquid biopsy next-generation sequencing companion diagnostic test. August 7, 2020. Accessed July 27, 2023. https://www.fda.gov/news-events/press-announcements/fda-approves-first-liquid-biopsy-next-generation-sequencing-companion-diagnostic-test 6. Guardant Galaxy Flyer. Guardant Health, Inc. Redwood City, CA.
7. Guardant360® Assay Specifications. Guardant Health, Inc. Redwood City, CA. 8. Cui W, Milner-Watts C, O’Sullivan H, et al. Up-front cell-free DNA next generation sequencing improves target identification in UK first line advanced non-small cell lung cancer (NSCLC) patients. Eur J Cancer. 2022;171:44-54. doi:10.1016/j.ejca.2022.05.012 9. Zhang Q, Luo J, Wu S, et al. Prognostic and predictive impact of circulating tumor DNA in patients with advanced cancers treated with immune checkpoint blockade. Cancer Discov. 2020;10(12):1842-1853. doi:10.1158/2159-8290.CD-20-0047 10. Guardant360® Response: Guide to Ordering Guardant360 Response. Guardant Health, Inc. Redwood City, CA. 11. Shields MD, Chen K, Dutcher G, Patel I, Pellini B. Making the rounds: exploring the role of circulating tumor DNA (ctDNA) in non-small cell lung cancer. Int J Mol Sci. 2022;23(16):9006. doi:10.3390/ijms23169006
12. Gilson P, Merlin JL, Harlé A. Deciphering tumour heterogeneity: from tissue to liquid biopsy. Cancers (Basel). 2022;14(6):1384. doi:10.3390/cancers14061384